Mylan Announces Final Approval For Meloxicam Tablets

Mylan Laboratories Inc.
(NYSE: MYL) today announced that the U.S. Food and Drug Administration has
granted final approval for Mylan Pharmaceuticals Inc.'s Abbreviated New
Drug Application for Meloxicam Tablets, 7.5 mg and 15 mg.


Meloxicam Tablets are indicated for the relief of the signs and
symptoms of osteoarthritis. They are the AB-rated generic equivalent of
Boehringer Ingelheim's Mobic(R) Tablets, which had annual U.S. sales of
approximately $1.1 billion for the 12 months ending March 31, 2006.
This product will be shipped immediately.


Mylan Laboratories Inc. is a leading pharmaceutical company with three
principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan Technologies Inc.
and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets
and distributes an extensive line of generic and proprietary products.
For more information about Mylan, please visit mylan/.


Mylan Laboratories Inc.

mylan/